Still, as IDH 1/2 mutations represent a relatively recently discovered driver mutation in myeloma, mutant IDH inhibition is now being investigated in humans, with IDH2-mutated patients in the MyDRUG protocol receiving enasidenib-based combinations (105). This evidence concerns the gene IDH2 and plasma cell myeloma.